Cargando…

A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth

Cripto-1 is a member of the EGF-CFC/FRL1/Cryptic family and is involved in embryonic development and carcinogenesis. We designed a novel anti-Cripto-1 artificial antibody and assessed the recognition to the antigen and the potential to suppress the growth of cancer stem cells. First, single chain an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hiroko, Zahra, Maram H., Takayanagi, Atushi, Seno, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915030/
https://www.ncbi.nlm.nih.gov/pubmed/33567764
http://dx.doi.org/10.3390/ijms22041709
_version_ 1783657142364930048
author Ishii, Hiroko
Zahra, Maram H.
Takayanagi, Atushi
Seno, Masaharu
author_facet Ishii, Hiroko
Zahra, Maram H.
Takayanagi, Atushi
Seno, Masaharu
author_sort Ishii, Hiroko
collection PubMed
description Cripto-1 is a member of the EGF-CFC/FRL1/Cryptic family and is involved in embryonic development and carcinogenesis. We designed a novel anti-Cripto-1 artificial antibody and assessed the recognition to the antigen and the potential to suppress the growth of cancer stem cells. First, single chain antibody clones were isolated by bio-panning with the affinity to recombinant Cripto-1 protein from our original phage-display library. Then, the variable regions of heavy chain VH and light chain VL in each clone were fused to constant regions of heavy chain CH and light chain CL regions respectively. These fused genes were expressed in ExpiCHO-S cells to produce artificial humanized antibodies against Cripto-1. After evaluation of the expression levels, one clone was selected and the anti-Cripto-1 antibody was produced and purified. The purified antibody showed affinity to recombinant Cripto-1 at 1.1 pmol and immunoreactivity to cancer tissues and cell lines. The antibody was available to detect the immunoreactivity in tissue microarrays of malignant tumors as well as in Cripto-1 overexpressing cells. Simultaneously, the antibody exhibited the potential to suppress the growth of human colon cancer derived GEO cells overexpressing Cripto-1 with IC(50) at approximately 110 nM. The artificially humanized antibody is proposed to be a good candidate to target cancer cells overexpressing Cripto-1.
format Online
Article
Text
id pubmed-7915030
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79150302021-03-01 A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth Ishii, Hiroko Zahra, Maram H. Takayanagi, Atushi Seno, Masaharu Int J Mol Sci Article Cripto-1 is a member of the EGF-CFC/FRL1/Cryptic family and is involved in embryonic development and carcinogenesis. We designed a novel anti-Cripto-1 artificial antibody and assessed the recognition to the antigen and the potential to suppress the growth of cancer stem cells. First, single chain antibody clones were isolated by bio-panning with the affinity to recombinant Cripto-1 protein from our original phage-display library. Then, the variable regions of heavy chain VH and light chain VL in each clone were fused to constant regions of heavy chain CH and light chain CL regions respectively. These fused genes were expressed in ExpiCHO-S cells to produce artificial humanized antibodies against Cripto-1. After evaluation of the expression levels, one clone was selected and the anti-Cripto-1 antibody was produced and purified. The purified antibody showed affinity to recombinant Cripto-1 at 1.1 pmol and immunoreactivity to cancer tissues and cell lines. The antibody was available to detect the immunoreactivity in tissue microarrays of malignant tumors as well as in Cripto-1 overexpressing cells. Simultaneously, the antibody exhibited the potential to suppress the growth of human colon cancer derived GEO cells overexpressing Cripto-1 with IC(50) at approximately 110 nM. The artificially humanized antibody is proposed to be a good candidate to target cancer cells overexpressing Cripto-1. MDPI 2021-02-08 /pmc/articles/PMC7915030/ /pubmed/33567764 http://dx.doi.org/10.3390/ijms22041709 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ishii, Hiroko
Zahra, Maram H.
Takayanagi, Atushi
Seno, Masaharu
A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
title A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
title_full A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
title_fullStr A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
title_full_unstemmed A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
title_short A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
title_sort novel artificially humanized anti-cripto-1 antibody suppressing cancer cell growth
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915030/
https://www.ncbi.nlm.nih.gov/pubmed/33567764
http://dx.doi.org/10.3390/ijms22041709
work_keys_str_mv AT ishiihiroko anovelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT zahramaramh anovelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT takayanagiatushi anovelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT senomasaharu anovelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT ishiihiroko novelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT zahramaramh novelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT takayanagiatushi novelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth
AT senomasaharu novelartificiallyhumanizedanticripto1antibodysuppressingcancercellgrowth